Endocrine and behavioural effects of transdermal buprenorphine in pain-suffering women of different reproductive ages

Endocrine Journal

Volumn 58, Issue 12, 2011, Pages 1071-1078

  Aurilio, Caterina ^a   Ceccarelli, Ilaria ^b   Pota, Vincenzo ^a   Sansone, Pasquale ^a   Massafra, Cosimo ^b   Barbarisi, Manlio ^a   Pace, Maria Caterina ^a   Passavanti, Maria Beatrice ^a   Bravi, Fabio ^c   Aloisi, Anna Maria ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c Department of Biometrics   (Italy)

Author keywords

Age; Cortisol; Gonadal hormones; Pain; Transdermal buprenorphine patch

Indexed keywords

ALANINE AMINOTRANSFERASE; ANDROSTANOLONE; ASPARTATE AMINOTRANSFERASE; BUPRENORPHINE; CREATININE; ESTRADIOL; FOLLITROPIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HYDROCORTISONE; LUTEINIZING HORMONE; NITROGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMATOCRIT; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HYPOGONADISM; MCGILL PAIN QUESTIONNAIRE; PAIN ASSESSMENT; POSTMENOPAUSE; PREMENOPAUSE; TREATMENT DURATION; UPREGULATION; VISUAL ANALOG SCALE;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; BUPRENORPHINE; CHRONIC PAIN; FEMALE; HUMANS; HYDROCORTISONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; POSTMENOPAUSE; PREMENOPAUSE; PROSPECTIVE STUDIES; TESTOSTERONE;

EID: 84855177054     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ11-0095     Document Type: Article

References (23)

1. Niv D, Devor M. (2007) Position paper of the European Federation of IASP Chapters (EFIC) on the subject of pain management. Eur J Pain 11:487-489.
2. Delitala G, Giusti M, Mazzocchi G, Granziera L, Tarditi W, Giordano G. (1983) Participation of endogenous opiates in regulation of the hypothalamic-pituitary-testicular axis in normal men. J Clin Endocrinol Metab 57:1277-1281.
3. Daniell HW. (2002) Hypogonadism in men consuming sustained-action oral opioids. J Pain 3:377-384.
4. Meczekalski B, Podfigurna-Stopa A, Warenik-Szymankiewicz A, Gennazzani AR. (2008) Functional hypothalamic amenorrhea: current view on neuroendocrine aberrations. Gynecol Endocrinol 24:4-11.
5. Aloisi AM, Aurilio C, Bachiocco V, Biasi G, Fiorenzani P, Pace MC, Paci V, Pari G, Passavanti G, Ravaioli L, Sindaco G, Vellucci R, Ceccarelli I. (2009) Endocrine consequences of opioid therapy. Psychoneuroendocrinology 34:S162-168.
6. Aloisi AM, Pari G, Ceccarelli I, Vecchi I, Ietta F, Lodi L, Paulesu L. (2005) Gender-related effects of chronic non-malignant pain and opioid therapy on plasma levels of macrophage migration inhibitory factor (MIF). Pain 115:142-151.
7. Cherrier MM. (2009) Testosterone effects on cognition in health and disease. Front Horm Res 37:150-162.
8. Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN. (2004) One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 29:1071-1081.
9. Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blakman MR, Harman SM, Resnick SM. (2004) Free testosterone and risk for Alzheimer disease in older men. Neurology 62:188-193.
10. Harbuz MS, Perveen-Gill Z, Lightman SL, Jessop DS. (1995) A protective role for testosterone in adjuvant-induced arthritis. Br J Rheumatol 34:1117-1122.
11. Aloisi AM, Ceccarelli I, Fiorenzani P, De Padova AM, Massafra C. (2004) Testosterone affects (pain-related) formalin-induced responses differently in male and female rats. Neurosci Lett 361:262-264.
12. Daniell HW. (2008) Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain 9:28-36.
13. Kress HG. (2009) Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 13:219-230.
14. Sittl R, Griessinger N, Likar R. (2003) Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 25:150-168.
15. Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, Mercadante S, Morlion B, Raffa RB, Sabatowski R, Sacerdote P, Torres LM, Weinbroum AA. (2010) Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract 10:428-450.
16. Griessinger N, Sittl R, Likar R. (2005) Transdermal buprenorphine in clinical practice. A post-marketing surveillance study in 13179 patients. Curr Med Res Opin 21:1147-1156.
17. Muriel C, Failde I, Micó JA, Neira M, Sanchez-Magro I. (2005) Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective observational clinical study. Clinical Therapeutics 27:451-462.
18. Bohme K, Likar R. (2003) Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study. Pain Clinic 15:193-202.
19. Ceccarelli I, De Padova AM, Fiorenzani P, Massafra C, Aloisi AM. (2006) Single opioid administration modifies gonadal steroids in both the CNS and plasma of male rats. Neuroscience 140:929-937.
20. Steel RGD, Torrie JH, Dickey DA. (1997) Principles and Procedures of Statistics. A Biometrical Approach, 3th Edition, McGraw-Hill International Book Company, London.
21. Trescot AM, Datta S, Lee M, Hansen H. (2008) Opioid pharmacology. Pain Physician 11:133-153.
22. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. (2006) Opioids for chronic non cancer pain: a meta-analysis of effectiveness and side effects. CMAJ 174:1589-1594.
23. Sanoja R, Cervero F. (2008) Estrogen modulation of ovariectomy-induced hyperalgesia in adult mice. Eur J Pain 12:573-581.